NCT04129931: PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study |
|
|
| Active, not recruiting | 2 | 395 | US | MCT, Breathe Better Diet (BBD), Clazakizumab, Anti-interleukin 6 monoclonal antibody, Anti-IL-6 mAb, BMS-945429, ALD518, Broncho-Vaxom, OM-85 BV VEGETAL, Imatinib Mesylate, Gleevec, Zoleta, Glivec, Ziatir, Cavosonstat, N91115, Placebo | University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI) | Asthma | 12/24 | 12/24 | | |
NCT04108377: Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma |
|
|
| Terminated | 1 | 5 | US | Roflumilast, Daliresp, Placebo, Placebo for Roflumilast | University of California, Davis | Asthma | 12/22 | 08/23 | | |
